Founded in 2017, Dimension Inx is a regenerative therapeutics company that designs, develops, and manufactures therapeutic products to restore tissue and organ function. The company owns four
Dimension Inx received FDA clearance of CMFlex in December of 2022. CMFlex is currently available to a limited number of key surgeons with a broader release to follow later in 2024.
The first jaw cases were performed by Dr.
CMFlex has also been used in dental socket preservation surgeries for future dental implant placement by Dr.
'These first cases are not only indicative of a new generation of biomaterials, but also highlight our technology platform's unique capability to rapidly create biomaterials that direct cell behavior to restore tissue and organ function. It is a proud moment for us to be able to demonstrate the value of therapeutics derived from integrating novel biomaterial design and 3D-printing approaches,' said Dr.
Dr.
About CMFlex
CMFlex is comprised primarily of hydroxyapatite, a naturally occurring mineral found in bone, combined with biodegradable polylactide-co-glycolide (PLG) polymer. Both materials have an extensive history demonstrating biocompatibility and clinical utility. Dimension Inx combines these base materials into a proprietary, microstructurally porous composite material, Hyperelastic Bone, as first published in Science Translational Medicine in 2016.
This unique, easily deployable bone repair material is then 3D printed into CMFlex. which has an engineered architecture with nano, micro, and macro-level features designed to promote natural bone regeneration after implantation, without the need for an invasive autograft.
The resulting product is one that surgeons can size for each patient and is uniquely capable of absorbing fluid, which enables it to control bleeding during surgery while assisting the bone remodeling process once implanted.
'After many years of research and development, we're proud to see the first bioprinting applications move into clinical use with patients,' said
The 3D-Bioplotter is a sophisticated extrusion-based 3D printer that processes liquids, melts, pastes, gels, or other materials, including cells, through a needle tip on a Swiss-made, 3-axis gantry system with high accuracy and repeatability, along with tight controls for temperature, sterility, and design. 3D-Bioplotter offers eight printheads with the widest range of temperatures in bioprinting - from 2-degreeC to 500-degreeC (35.6-degreeF to 932-degreeF) - enabling complex, multi-material medical parts.
3D-Bioplotter is also the world's most cited and researched bioprinter in peer-reviewed scientific and medical journals, with more than 2,490 citations and more than 640 research papers directly produced with the system.
About
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to the risks and uncertainties set forth in
Contact:
Tel: (857) 504-1084
Email: DesktopMetalIR@icrinc.com
Email: sarahwebster@desktopmetal.com
Tel: (313) 715-6988
(C) 2023 Electronic News Publishing, source